key: cord-0817850-xzfnprci
authors: Abrams-Downey, Alexandra; Saabiye, Joseph; Vidaurrazaga, Monica
title: Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials
date: 2020-06-05
journal: Eur Urol Focus
DOI: 10.1016/j.euf.2020.05.019
sha: 5b4c3a9d24cfa20950217e8b1a172944be62aa70
doc_id: 817850
cord_uid: xzfnprci

nan

Currently there are no therapeutics approved by the US point) compared to placebo (p = 0.001) [22] . On May 1, 2020,

a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . damage seen in COVID-19 is due to a "cytokine storm", 100 release of proinflammatory cytokines including IL-6 

National Institutes of Health. NIAID strategic plan for COVID-19

National Institutes of Health. NIH clinical trial shows remdesivir 205 accelerates recovery from advanced COVID-19

Fact sheet for health care pro-209 viders. Emergency use authorization (EUA) of remdesivir (GS-210 5734)

Some observations of treating cases of diphtheria

Meta-analysis: con-213 valescent blood products for Spanish influenza pneumonia: a future 214 H5N1 treatment?

The effective-216 ness of convalescent plasma and hyperimmune immunoglobulin 217 for the treatment of severe acute respiratory infections of viral 218 etiology: a systematic review and exploratory meta-analysis

Hyperimmune IV immunoglobulin 220 treatment: a multicenter double-blind randomized controlled trial 221 for patients with severe 2009 influenza A (H1N1) infection

Evaluation of 224 convalescent plasma for Ebola virus disease in Guinea

Testing an old therapy against a new disease: convalescent 227 plasma for COVID-19

Treatment of 5 critically ill patients 230 with COVID-19 with convalescent plasma

Effect of convale Q8 scent plasma therapy 233 on viral shedding and survival in COVID-19 patients

Effectiveness of convalescent plasma 236 therapy in severe COVID-19 patients

Early safety indicators 239 of COVID-19 convalescent plasma in 5,000 patients. medRxiv pre-240 print

cytokine storm in SARS patients

Analysis of serum cytokines in patients with 244 severe acute respiratory syndrome

Cytokine release syn-246

FDA approval summary: tocilizumab for 249 syndrome

Effective treatment of severe COVID-19 patients 252 with tocilizumab

Tocilizumab 254 COVID-19 pneumonia

Press release. Regeneron and Sanofi provide update on 257

Phase 2/3 adaptive-designed trial of KEVZARA (sarilumab) in 258 hospitalized COVID-19 patients. Regeneron

Ethics of random-260

Treating COVID-19-off-label drug use, compassionate use, and 263 randomized clinical trials during pandemics

Finding effective treatments for COVID